ABVC - CIK 0001173313
The table below shows ABVC BIOPHARMA, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.99M | -$1.81M | -$4.19M | -$7.40M | -$7.60M | -$4.56M |
| Capital expenditure | - | - | $21.20K | $119.69K | $17.50K | - |
| Investing cash flow | -$1.21M | - | -$360.19K | -$1.72M | -$805.97K | -$225.43K |
| Dividends paid | - | - | - | - | - |
ABVC BIOPHARMA, INC. reported operating cash flow of -$2.99M for fiscal year 2025. That is down 65.1% from -$1.81M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$3.47M (FY 2016) to -$2.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $4.64M | $1.98M | $3.87M | $4.01M | $10.00M | $9.57M |